Business
Neurothera Labs Announces Adoption of Semi-Annual Reporting
(TheNewswire) May 20, 2026 – TheNewswire - Toronto, Ontario, Canada - Neurothera L...
About this update from Neurothera Labs Inc.
[{"type":"text","content":"Neurothera Labs Announces Adoption of Semi-Annual Reporting\n(TheNewswire)\n\n\nMay 20, 2026 – TheNewswire -\nToronto, Ontario, Canada - Neurothera Labs Inc.\n(TSXV: NTLX) (“Neurothera” or the “Company”), a\nclinical-stage biotech company and a majority-owned subsidiary of\nSciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), announces\nthat it has adopted a semi-annual financial reporting\n(\"SAR\") framework, effective immediately. This change is being\nmade pursuant to the Coordinated Blanket Order 51-933 Exemptions to\nPermit Semi-Annual Reporting for Certain Venture Issuers\n(\"CBO 51-933\").\n\n\n \n\n\nCBO 51-933 allows eligible venture issuers to\nvoluntarily move from a quarterly to a\nsemi-annual financial reporting framework. \n\n\nTransition Details – Neurothera’s fiscal year ends on\nDecember 31. Under the SAR framework, the Company will be exempt from\nfiling interim financial reports and related Management Discussion\n& Analysis (“MD&A”) for its first and third quarters\nfor so long as it continues to meet eligibility criteria under CBO\n51-933. \n\n\nBy adopting the SAR, Neurothera aims to reduce the\nadministrative and financial burden associated with quarterly\nreporting, allowing management to focus resources on advancement of\ndifferent projects.\n\n\n\n\nInitial Interim Period: The Company will not file an interim report for the first\nquarter (Q1) ending March 31, 2026 and for the third quarter (Q3)\nending September 30, 2026. \n\n\n\nOngoing Reporting: Neurothera will\ncontinue to file audited annual consolidated financial statements (due\nwithin 120 days of December 31, 2026), and six-month interim financial\nreports (due within 60 days of June 30). \n\n\n\nContinued Disclosure: The Company remains committed to timely disclosure and will\ncontinue to report all material changes and significant developments\nas required under National Instrument 51-102. \n\n\n\nEligibility:\nNeurothera confirms it\nmeets the pilot program's eligibility criteria, which includes\nbeing a venture issuer with annual revenues of less than$10 million\nand maintaining a clean 12-month continuous disclosure\nrecord. \n\n\n\nContinued Participation: Should the Company cease to continue participating in the\nSAR Pilot Program, it will...